Reports Q3 revenue $60.94B, consensus $62.24B. “An excellent third quarter extends our FY26 momentum, due to the durability and resilience of our business,” said Jason Hollar, CEO of Cardinal Health (CAH). “We were pleased to see strong operating performance led by Pharmaceutical and Specialty Solutions and our three growth businesses, positioning us for long-term value creation and giving us the confidence to again raise our fiscal 2026 outlook.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Notable companies reporting before tomorrow’s open
- Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
- Cardinal Health Earns Buy Rating on High-Margin Growth Segments and Double-Digit EPS Outlook
- Cardinal Health initiated with an Outperform at William Blair
- CAH Earnings Report this Week: Is It a Buy, Ahead of Earnings?